XML 16 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727
Intangible Assets
6 Months Ended
Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

NOTE D — INTANGIBLE ASSETS

Intangible assets as of June 30, 2015 and December 31, 2014 consisted of the following (in thousands):

 

     Amortization
Period
   June 30, 2015  
          COST      Accumulated
Amortization
     Net  

Customer Relationships

   156 months    $ 1,930       $ 146       $ 1,784   

Support Vector Machine (SVM) technology

   108 months      500         185         315   

Laboratory developed test (LDT) technology

   164 months      1,482         361         1,121   

Flow Cytometry and Cytogenetics technology

   202 months      1,000         198         802   
     

 

 

    

 

 

    

 

 

 

Total

      $ 4,912       $ 890       $ 4,022   
     

 

 

    

 

 

    

 

 

 

 

     Amortization
Period
   December 31, 2014  
          COST      Accumulated
Amortization
     Net  

Customer Relationships

   156 months    $ 1,930       $ 71       $ 1,859   

Support Vector Machine (SVM) technology

   108 months      500         167         333   

Laboratory developed test (LDT) technology

   164 months      1,482         297         1,185   

Flow Cytometry and Cytogenetics technology

   202 months      1,000         165         835   
     

 

 

    

 

 

    

 

 

 

Total

      $ 4,912       $ 700       $ 4,212   
     

 

 

    

 

 

    

 

 

 

We recorded approximately $97,000 and $55,000 in straight-line amortization expense of intangibles in the three months ended June 30, 2015 and 2014, respectively. We recorded approximately $190,000 and $111,000 in straight-line amortization expense of intangibles in the six months ended June 30, 2015 and 2014, respectively. The Company recorded amortization expense from customer relationships as a general and administrative expense. We will continue to record the amortization of the Support Vector Machine (SVM) technology, the Laboratory developed tests (LDT) technology and the Flow Cytometry and Cytogenetics technology intangibles as a research and development expense until the time that we have products, services or cost savings directly attributable to these intangible assets that would require that it be recorded in cost of goods sold.

The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of June 30, 2015 is as follows (in thousands):

 

Year Ending December 31,

      

Remainder of 2015

   $ 186   

2016

     372   

2017

     372   

2018

     372   

2019

     372   

2020

     372   

Thereafter

     1,976   
  

 

 

 

Total

   $ 4,022